tumor recurrence

Related by string. * Tumor . Tumors . TUMOR . tumors . TUMORS : malignant brain tumor . cancerous brain tumor . battling brain tumor . brain tumor . cancerous tumor removed . remove malignant tumor / recurrences . Recurrence . Recurrences : prevent recurrence . biochemical recurrence . Oncotype DX Recurrence Score . CDI recurrence . breast cancer recurrence . adenoma recurrence * *

Related by context. All words. (Click for frequent words.) 78 distant metastases 75 distant metastasis 73 metastatic disease 72 metastases 72 neoadjuvant chemotherapy 71 liver metastases 70 biochemical recurrence 69 pCR 69 HNSCC 69 advanced adenomas 69 CMV disease 69 locoregional recurrence 69 preoperative chemotherapy 68 metastatic lesions 68 metastatic tumors 68 neoadjuvant therapy 68 metastatic cancer 68 brain metastases 68 metastatic RCC 68 PCa 68 cystectomy 68 disease progression 68 PSADT 67 recurrent VTE 67 lymph node metastasis 67 metastatic prostate cancer 67 ALND 67 curative resection 67 chemoradiotherapy 67 advanced adenoma 67 nodal metastases 67 breast carcinoma 67 androgen deprivation 67 adjuvant radiation 67 locoregional 66 lymph node metastases 66 micrometastases 66 adjuvant radiotherapy 66 colorectal tumors 66 biochemical relapse 66 tumor shrinkage 66 pancreatic adenocarcinoma 66 lymph node involvement 66 axillary dissection 66 R0 resection 66 differentiated thyroid 66 EBRT 66 adenoma 66 liver metastasis 66 sustained virological response 65 metastatic renal cell carcinoma 65 neoadjuvant 65 cerebral vasospasm 65 recurrences 65 contralateral breast cancer 65 prostate cancer CaP 65 virologic response 65 CIN2 + 65 definite stent thrombosis 65 debulking surgery 65 lymphocytosis 65 thromboembolic events 65 ADPKD 65 pT3 65 adjuvant chemotherapy 65 CMV infection 65 malignant pleural mesothelioma 65 perioperative complications 65 HSCT 65 lung metastases 65 radical nephrectomy 64 contralateral breast 64 malignancy 64 renal tumors 64 cytoreductive surgery 64 complete cytogenetic response 64 complete cytogenetic 64 tumor progression 64 thrombotic complications 64 microalbuminuria 64 chemoradiation 64 lung metastasis 64 breast cancer recurrence 64 recurrent glioblastoma multiforme 64 Doxil ® 64 tumor resection 64 postoperative chemotherapy 64 tumors 64 CaP 64 SLNB 64 operable breast cancer 64 prostate adenocarcinoma 64 mRCC 64 sustained virologic response 64 lymphadenectomy 64 urothelial carcinoma 64 clinically localized prostate 64 lung tumors 64 CIN3 63 ipsilateral stroke 63 epithelial tumors 63 postoperative mortality 63 SUVmax 63 precursor lesions 63 malignant lesions 63 mycophenolate mofetil 63 endometrial carcinoma 63 stage IIIB 63 metachronous 63 endometrial hyperplasia 63 postoperative complication 63 recurrent prostate cancer 63 epithelial ovarian cancer 63 lymph node dissection 63 zoledronic acid 63 hematologic toxicity 63 virologic failure 63 severe neutropenia 63 stage IIIA 63 imatinib therapy 63 thyroglobulin 63 GIST tumors 63 histologic subtype 63 colorectal adenoma 63 infarct size 63 unresectable 63 anthracycline taxane 63 colorectal carcinoma 63 PSA nadir 63 prostate cancer PCa 63 unresectable tumors 63 breast carcinomas 63 cranial radiation 63 bladder tumors 63 HER2 expression 63 gastric adenocarcinoma 63 grade gliomas 63 prospectively defined 63 bone metastases 63 endometrial cancers 63 bronchopulmonary dysplasia 63 adjuvant therapies 63 hepatocellular carcinoma 63 thymoma 63 metastatic 63 cytogenetic response 63 cytoreduction 63 ependymoma 63 median PFS 63 liver transplant recipients 63 micrometastasis 63 GISTs 63 parathyroid 63 evaluable patients 63 gastric cancer 63 adjuvant therapy 63 colon tumors 63 grade cervical intraepithelial 63 bone metastasis 63 pT2 63 CR nPR 62 urothelial cancer 62 radical prostatectomy RP 62 chlorambucil 62 CCyR 62 colorectal liver metastases 62 adenomatous polyps 62 pelvic lymphadenectomy 62 lobular carcinoma 62 reinfarction 62 peritoneal cancer 62 adenocarcinomas 62 invasive ductal 62 tumor 62 rebleeding 62 graft dysfunction 62 polyp recurrence 62 underwent resection 62 heavily pretreated 62 IV NSCLC 62 ximelagatran 62 mg kg dose 62 pneumonectomy 62 carcinoma 62 HBeAg seroconversion 62 radioiodine therapy 62 adenomas 62 Adjuvant chemotherapy 62 nodal metastasis 62 malignancies 62 aneurysm rupture 62 neoplasia 62 invasive carcinoma 62 liver resection 62 orchiectomy 62 cervical carcinoma 62 recanalization 62 atypical hyperplasia 62 ipsilateral breast 62 tamoxifen therapy 62 neuroendocrine tumors 62 TACE 62 node metastases 62 premalignant lesions 62 malignant growths 62 cervical intraepithelial neoplasia 62 H. pylori eradication 62 thromboembolic 62 basal cell carcinoma BCC 62 NMIBC 62 hepatic metastases 62 pulmonary metastases 62 reintervention 62 MGUS 62 TNF antagonist 62 axillary nodes 62 systemic toxicity 62 atypia 62 Kaplan Meier analysis 62 platelet reactivity 62 EUS FNA 62 mammary tumors 62 glycated hemoglobin levels 62 hepatectomy 62 intravenous bisphosphonates 62 renal cell carcinomas 62 axillary node dissection 62 vertebral fracture 62 FOLFOX4 62 colectomy 62 KRAS mutation 62 metastatic malignant melanoma 62 carotid stenosis 62 nonmetastatic 62 Recurrence Score 62 gastrointestinal stromal tumor GIST 62 HGPIN 62 androgen suppression therapy 62 axillary node 62 lobular cancer 62 radical cystectomy 62 VT VF 61 tumor regression 61 hemorrhagic complications 61 premalignant 61 TRUS biopsy 61 prostate cancer CRPC 61 ovarian tumors 61 CR CRu 61 HBeAg 61 HBeAg negative 61 histologic 61 revascularization procedures 61 QTc prolongation 61 progression TTP 61 metastatic lung cancer 61 intact parathyroid hormone 61 locoregional disease 61 acute GVHD 61 cholangiocarcinoma 61 follicular lymphoma 61 histologically confirmed 61 radical prostatectomy 61 hypercalcemia 61 postoperative AF 61 perioperative mortality 61 K ras mutations 61 extracapsular extension 61 tumor regressions 61 virological response 61 invasive breast cancer 61 transaminase levels 61 FDG PET 61 papillary renal cell carcinoma 61 adrenalectomy 61 carcinoid tumor 61 atherosclerotic disease 61 recurrent NSCLC 61 hepatocellular carcinomas 61 ischemic lesions 61 thrombotic events 61 colorectal cancer 61 occult metastases 61 invasive aspergillosis 61 nodal dissection 61 intestinal metaplasia 61 gefitinib 61 low expressors 61 EGFR mutations 61 fallopian tube carcinoma 61 colorectal adenomas 61 prognostic variables 61 external beam radiotherapy 61 F FDG PET 61 cutaneous melanoma 61 HER2 negative 61 nonmelanoma skin cancers 61 malignant neoplasm 61 virologic responses 61 advanced neoplasia 61 ventricular dysfunction 61 serous ovarian cancer 61 carcinoid 61 EXJADE 61 intracranial hemorrhage ICH 61 antibody titer 61 chlamydial infection 61 bone resorption 61 catheter angiography 61 mCRC patients 61 cisplatin chemotherapy 61 vandetanib 61 BRCA mutations 61 tumor histology 61 genotypic resistance 61 transurethral resection 61 HBeAg positive patients 61 acute aortic dissection 61 resectable 61 allogeneic stem cell 61 metastatic GIST 61 Thal Dex 61 HER2 overexpression 61 antiplatelet therapy 61 neoadjuvant treatment 60 retransplantation 60 transitional cell carcinoma 60 colorectal neoplasms 60 heavily pretreated patients 60 intraoperative complications 60 intravesical therapy 60 ovarian carcinoma 60 ovarian cancer 60 paroxysmal AF 60 medically inoperable 60 leukemia AML 60 Tumor shrinkage 60 angiographic restenosis 60 non squamous NSCLC 60 chronic GVHD 60 neoplastic lesions 60 allograft rejection 60 postoperative morbidity 60 metastasis 60 imatinib 60 PCNSL 60 periprocedural 60 nonfatal MI 60 antitumor effect 60 completely resected 60 variceal hemorrhage 60 posttransplant 60 sentinel lymph node biopsy 60 T1c 60 NNRTI resistance 60 breast tumors 60 esophageal carcinoma 60 HER2 positive metastatic breast 60 mutated KRAS 60 recurrent ovarian cancer 60 perioperative morbidity 60 troponin T 60 FOLPI 60 bilateral oophorectomy 60 ductal cancer 60 mesotheliomas 60 acute GvHD 60 LV dysfunction 60 octreotide LAR 60 tumor lysis syndrome 60 nonmetastatic prostate cancer 60 relapsed ovarian cancer 60 ICD implantation 60 peritoneal carcinomatosis 60 glomerular filtration 60 osteosarcomas 60 histological subtype 60 nephrectomy 60 response pCR 60 pre cancerous polyps 60 prostate biopsy 60 renal cell carcinoma 60 Tavocept 60 BRCA2 mutation carriers 60 metastatic gastric 60 urothelial bladder cancer 60 atheroma volume 60 pre malignant lesions 60 microvascular complications 60 nonischemic 60 Median survival 60 androgen ablation 60 fibrinolysis 60 small lymphocytic lymphoma 60 undergoing coronary angiography 60 grade glioma 60 posaconazole 60 acute leukemias 60 medullary thyroid cancer 60 sunitinib 60 hepatorenal syndrome 60 decitabine 60 neurodevelopmental impairment 60 carcinoids 60 neoplastic cells 60 HER2 positive breast cancer 60 bladder cancers 60 sleeve lobectomy 60 bevacizumab 60 macroalbuminuria 60 ocular toxicity 60 chemosensitivity 60 trastuzumab 60 adalimumab 60 prior chemotherapy regimens 60 PITX2 60 B7 H3 60 virological failure 60 castration resistant prostate cancer 60 metastatic bladder 60 A1c levels 60 BRCA1 mutation carriers 60 cervical lymph nodes 60 MACCE 60 renal scarring 60 CMV infections 60 liver fibrosis 60 HBV infection 60 radiochemotherapy 60 KRAS mutations 60 serum creatinine levels 60 idraparinux 60 breast cancer metastasis 60 superficial bladder cancer 60 VUR 60 #.#ng/ml 60 cranial irradiation 60 histologically proven 60 recurrent venous thromboembolism 60 pheochromocytoma 60 prostate carcinoma 60 neoplasm 60 Hurthle cell 60 coronary artery stenosis 60 antithrombotic therapy 60 intensive statin therapy 60 variceal bleeding 60 imetelstat 60 allogeneic SCT 60 TP# mutations 60 mammographic density 60 BCR ABL mutations 60 perfusion abnormalities 60 axillary lymph node 60 bleomycin 60 thromboembolic disease 59 recurrent myocardial infarction 59 surgical debulking 59 antiangiogenic therapy 59 chromosomal mutations 59 timepoint 59 graft occlusion 59 mTOR inhibitors 59 uveal melanoma 59 postoperative complications 59 gout flares 59 serum testosterone 59 atherosclerotic lesions 59 hepatocellular carcinoma HCC 59 intestinal polyps 59 pericardial effusion 59 myocardial infarction MI 59 renal toxicity 59 neurologic progression 59 postoperative infection 59 estimated glomerular filtration 59 renal carcinoma 59 sirolimus stent 59 peginterferon 59 hyperparathyroidism 59 concurrent chemoradiation 59 metastatic NSCLC 59 ALT flares 59 IV bisphosphonates 59 anti apoptotic proteins 59 hepatic fibrosis 59 undetectable HBV DNA 59 repeat revascularization 59 detectable HCV RNA 59 nephrotoxicity 59 repigmentation 59 chemoresistant 59 sentinel node 59 metastatic cancers 59 pathologic fractures 59 upper gastrointestinal bleeding 59 gastrointestinal stromal tumor 59 nasopharyngeal carcinoma 59 pre cancerous lesions 59 taxane chemotherapy 59 serum phosphate 59 nonalcoholic steatohepatitis NASH 59 DMARD 59 nab paclitaxel 59 axillary lymph nodes 59 annualized relapse 59 azacitidine 59 asymptomatic carotid stenosis 59 seminal vesicle invasion 59 neointimal hyperplasia 59 febrile neutropenia 59 varices 59 colorectal cancer CRC 59 CsA 59 elevated CRP 59 androgen suppression 59 Radical prostatectomy 59 cisplatin resistant 59 cardiac dysfunction 59 proliferative diabetic retinopathy 59 HbF 59 situ LCIS 59 myocardial ischemia 59 thromboembolism 59 seminoma 59 cervical lesions 59 lesions 59 PTLD 59 Neoadjuvant 59 bladder carcinoma 59 BRCA mutation carriers 59 temsirolimus 59 PASI scores 59 thyroid nodules 59 noncardiac 59 postoperative radiotherapy 59 RECIST Response Evaluation Criteria 59 PAOD 59 prostate tumor 59 pegylated liposomal doxorubicin 59 proteinuria 59 abnormal mammograms 59 mutated K ras 59 RECIST 59 carcinomas 59 patients undergoing CABG 59 cinacalcet 59 squamous cell carcinoma SCC 59 adverse cytogenetics 59 5FU 59 underwent surgical resection 59 postoperative pulmonary 59 ischemic cardiomyopathy 59 patients evaluable 59 cerebrovascular events 59 sorafenib 59 skeletal metastases 59 vaginal hysterectomy 59 squamous cell lung cancer 59 pancreatic tumor 59 malignant transformation 59 DAPT 59 grade dysplasia 59 platinum refractory 59 leukocyte count 59 hormonal therapy 59 BRAF mutation 59 bortezomib 59 neoplasms 59 nondiabetic patients 59 remission CR 59 carcinoid tumors 59 nonresponders 59 ductal breast cancer 59 subclinical hypothyroidism 59 hypoperfusion 59 GnRH agonist 59 anastrozole 59 metastatic malignant 59 CLL cells 59 clodronate 59 ductal carcinomas 59 pleural mesothelioma 59 gastrointestinal stromal tumors 59 precancerous condition 59 venous blood clots 59 NSCLC 59 thromboembolic complications 59 prognostic factors 59 contrast induced nephropathy 59 soft tissue sarcomas 59 sentinel node biopsy 59 seminomas 59 adenoma recurrence 59 sentinel nodes 59 TEAEs 59 hepatotoxicity 59 Kaplan Meier estimates 59 HER2 positive cancers 59 malignant lymphoma 59 LVEF 59 melanoma tumors 59 eplerenone 59 palliation 59 corticosteroid therapy 59 revascularizations 59 edifoligide 59 invasive candidiasis 59 KRAS mutant tumors 59 oophorectomy 59 specific antigen PSA 59 parathyroid carcinoma 59 hepatocellular cancer 59 taxane therapy 59 thoracoscopic lobectomy 59 cell carcinoma 59 fibrosis 59 spontaneous preterm delivery 59 cetuximab 59 KRAS mutations occur 59 Toxicities 59 evaluable 59 chemoembolization 59 sporadic ALS 59 binary restenosis 59 cutaneous squamous cell carcinoma 59 DFMO 59 partial remissions 59 colorectal adenocarcinoma 59 Recurrence 59 5-FU/LV 59 hyperkalemia 59 TURP 59 recurrent miscarriage 59 invasive coronary angiography 59 tumoral 59 severe oral mucositis 59 breast cancer recurrences 59 progesterone receptor negative 59 serum calcium levels 59 FDG uptake 59 oral clodronate 58 relapsed MM 58 coronary stenosis 58 basal cell carcinomas 58 cT3 prostate cancer 58 bendamustine 58 colorectal tumor 58 Partial Responses 58 tumor subtypes 58 RECIST criteria 58 hsCRP levels 58 coronary revascularization 58 leukemia ALL 58 epirubicin 58 stent implantation 58 hepatic resection 58 pancreatectomy 58 CIN2 58 prostatic adenocarcinoma 58 precancerous polyp 58 MALT lymphoma 58 choroidal neovascularization CNV 58 activating mutations 58 haematopoietic 58 erlotinib 58 cytotoxic chemotherapy 58 MS relapses 58 CLL SLL 58 hepatic toxicity 58 immunosuppressive medication 58 mg/m2 dose 58 5-fluorouracil/leucovorin 58 achieved ACR# 58 bacteriuria 58 dasatinib 58 intracerebral hemorrhage 58 radiotherapy RT 58 renal transplantation 58 lichen planus 58 oblimersen 58 serum clusterin levels 58 CDI recurrence 58 conventional angiography 58 mucinous 58 sarcoma 58 glioblastomas 58 cardiotoxicity 58 cerebral infarction 58 benign lesions 58 T1DM 58 colorectal polyp 58 thyroid carcinoma 58 bowel resection 58 seropositive patients 58 WT1 58 endarterectomy 58 infarcts 58 colorectal cancers 58 serum urate levels 58 recurrence 58 idarubicin 58 metastatic lesion 58 albuminuria 58 atypical fractures 58 HCV genotype 58 TORISEL 58 CTEPH 58 gastric carcinoma 58 recurrent metastatic 58 retroperitoneal 58 fondaparinux 58 dysplastic lesions 58 venous thromboembolism 58 transgene expression 58 Subgroup analyzes 58 plasma uric acid 58 free survival PFS 58 serum PSA 58 HbA 1c levels 58 resected 58 Recurrences 58 mRNA expression 58 severe rotavirus gastroenteritis 58 complete remissions 58 tumor necrosis 58 undergoing radical prostatectomy 58 hippocampal atrophy 58 atypical ductal hyperplasia 58 basal cell nevus syndrome 58 clinically detectable 58 microvessel density 58 nonoperative 58 post thrombotic syndrome 58 hamartomas 58 HER2 positive 58 pathologic 58 T2DM 58 liver histology 58 docetaxel chemotherapy 58 total thyroidectomy 58 medulloblastoma 58 TNF α 58 postop 58 alanine aminotransferase ALT 58 surrogate endpoint 58 IgA deficiency 58 salpingo oophorectomy 58 invasive carcinomas 58 median survivals 58 gefitinib Iressa 58 confidence interval #.#-#.# 58 FOLFOX6 58 spontaneous bacterial peritonitis 58 colorectal polyps 58 neutrophil counts 58 leiomyoma 58 Sustained Virological Response 58 Hepatocellular Carcinoma HCC 58 wedge resection 58 intima media thickness 58 severe exacerbations 58 ruboxistaurin 58 vinorelbine 58 precancerous cervical lesions 58 symptomatic VTE 58 decompensated cirrhosis 58 beta blocker therapy 58 clinicopathological features 58 malignant polyps 58 astrocytomas 58 tumor regrowth 58 nonvertebral fractures 58 HER2 positive tumors 58 ALCL 58 rFVIIa 58 systolic dysfunction 58 prostate cancers 58 lymphadenopathy 58 gemcitabine 58 chemo radiotherapy 58 carboplatin paclitaxel 58 astrocytoma 58 MetS 58 transfusion syndrome 58 alkaline phosphatase ALP 58 nonsmall cell lung cancer 58 EGFR mutation 58 reoperation 58 prednisone prednisolone 58 ribavirin therapy 58 esophagectomy 58 chromosomal aberrations 58 myeloproliferative disorder 58 sarcomatoid 58 PNH patients 58 % CI #.#-#.# [007] 58 flutamide 58 undetectable PSA 58 amyloid deposition 58 resected pancreatic cancer 58 GVHD 58 neoadjuvant radiation 58 cisplatin 58 estramustine 58 STRIDE PD 58 hormone refractory 58 hypermethylation 58 myocardial infarctions 58 carotid IMT 58 EGFR inhibitors 58 XIENCE V PROMUS Stent 58 neovascular 58 neuroblastomas 58 artery stenosis 58 myelodysplastic syndrome MDS 58 elevated ALT 58 fulvestrant 58 TroVax ® 58 APTIVUS r 58 smoldering myeloma 58 chemoradiation therapy 58 EGFR TKI 58 MYCN amplification 58 lobectomy 58 atherogenic dyslipidemia 58 defibrotide 58 thrombocytopenic 58 radiographic progression 58 autologous transplants 58 NATRECOR R 58 cystic lesions 58 Hashimoto thyroiditis 58 mucosal lesions 58 lobular breast cancer 58 aminotransferases 58 HNPCC 58 papillary carcinoma 58 % CI #.#-#.# [003] 58 fibrinolytic 58 postoperative atrial fibrillation 58 supratentorial 58 Immunohistochemical staining 58 immunohistochemical staining 58 leiomyosarcoma 58 abdominal hysterectomy 58 gastrointestinal cancers 58 thrombocytopenic patients 57 biliary tract cancer 57 Subgroup analysis 57 hyperoxaluria 57 metastatic breast cancer 57 reperfusion injury 57 arterial calcification 57 ertapenem 57 restenosis 57 spontaneous preterm birth 57 pancreatic carcinoma 57 NGAL 57 prognostic indicators 57 hormone receptor negative 57 dacarbazine 57 leukemia CLL 57 prognostic significance 57 undetectable HCV RNA 57 cilostazol 57 endocrine therapy 57 hemodynamic instability 57 prognostic indicator 57 varicocele 57 metastatic prostate 57 fluorouracil 57 HbA1c levels 57 autologous SCT 57 baseline LDH 57 pathologic diagnosis 57 confidence interval CI 57 histopathologic examination 57 acute myelogenous leukemia AML 57 mitoxantrone 57 estrogen receptor negative 57 trastuzumab Herceptin ® 57 imipenem 57 myelodysplastic syndromes MDS 57 colorectal cancer liver metastases 57 neoplasias 57 FOLFIRI 57 BRCA1 mutations 57 HPV-#/# 57 prostate cancer metastases 57 abiraterone 57 cabazitaxel 57 breast endometrial 57 Events MACE 57 recurrent GBM 57 EDSS scores 57 core needle biopsy 57 anemia hemoglobin 57 parathyroidectomy 57 colorectal neoplasia 57 hyperplastic 57 unresectable stage 57 selenium supplementation 57 node dissection 57 Cytoxan 57 cancer mCRC 57 KRAS wild 57 EBV infection 57 hormone receptor positive 57 recurrent DVT 57 topotecan 57 MitraClip device 57 postprocedure 57 allogeneic bone marrow 57 serum HCV RNA 57 femoral neck fracture 57 renal flares 57 allogeneic transplant 57 myeloablative 57 papillary thyroid carcinoma 57 poorer prognosis 57 percutaneous biopsy 57 pamidronate 57 TIMP 57 refractory NSCLC 57 allogeneic HSCT 57 Telintra 57 adnexal mass 57 #Gy 57 partial nephrectomy 57 aromatase inhibitor therapy 57 curable cancers 57 venous thromboembolic events 57 de ath 57 receiving VICTRELIS 57 dose cytarabine 57 placebo dexamethasone 57 lymphovascular invasion 57 baseline HbA1c 57 relapsed SCLC 57 malperfusion 57 fibrinolytic therapy 57 invasive fungal infection 57 HER2 amplification 57 preoperatively 57 Cholangiocarcinoma 57 resection 57 hematopoietic cancers 57 ejection fractions 57 nutlin 3a 57 bowel cancers 57 lobular carcinomas 57 revascularization procedure 57 Circulating tumor cells 57 autoantibodies 57 recurrent ischemia 57 vitreous hemorrhage 57 Wilms tumor 57 vestibular schwannomas 57 myocardial infarction 57 delayed CINV 57 choroidal neovascularization 57 T1a 57 heterotaxy 57 microvascular disease 57 APOL1 57 elevated triglyceride levels 57 CIMZIA ™ 57 venous thrombosis 57 endometrial cancer 57 pulmonary metastasis 57 timepoints 57 anterior uveitis 57 papillary thyroid cancer 57 oropharyngeal cancer 57 CrCl 57 neurologic complications 57 localized prostate cancer 57 myeloperoxidase 57 papillary RCC 57 anthracycline containing 57 esophagitis 57 adenocarcinoma 57 Sjögren syndrome 57 Ishak fibrosis score 57 para aortic 57 pituitary adenomas 57 palifermin 57 localized renal 57 liver biopsies 57 Metastatic 57 renal dysfunction 57 T2 lesions 57 β blockers 57 seroconversion 57 metastatic melanoma 57 hip BMD 57 adenomatous 57 leiomyomas

Back to home page